Ventricular Arrhythmia Suppression by Magnesium Treatment after Coronary Artery Bypass Surgery

Parikka1, Toivonen, Verkkala

  • 1Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

Insights

Intravenous magnesium sulfate administration effectively reduces ventricular arrhythmias following coronary artery bypass grafting (CABG). This treatment helps correct the common postoperative decline in serum magnesium levels, improving patient outcomes.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Clinical Pharmacology

Background:

  • Ventricular arrhythmias are common after coronary artery bypass grafting (CABG).
  • Postoperative hypomagnesemia frequently occurs in CABG patients.
  • A potential link exists between low magnesium levels and ventricular arrhythmias post-CABG.

Purpose of the Study:

  • To investigate if the decline in serum magnesium levels causes ventricular arrhythmias after CABG.
  • To determine if intravenous magnesium administration can reduce the incidence of these arrhythmias.

Main Methods:

  • A randomized controlled trial involving 140 CABG patients.
  • Patients received either 70 mmol of magnesium sulfate or a placebo over two days.
  • Arrhythmias were monitored using 48-hour Holter recordings on the third postoperative day.

Main Results:

  • Magnesium sulfate administration significantly increased serum magnesium levels compared to placebo (1.09 vs 0.77 mmol/l).
  • The incidence of ventricular premature complexes (VPCs) was reduced in the magnesium group (4 vs 12 VPCs/h).
  • Complex ventricular arrhythmias (Lown grade 2-5) were significantly less frequent in patients receiving magnesium (19% vs 41%).

Conclusions:

  • Correcting the postoperative decline in serum magnesium concentration reduces early VPCs and complex ventricular arrhythmias after CABG.
  • Patients with extensive coronary artery disease and those on preoperative diuretic therapy may benefit most from magnesium treatment.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...